Keeping trial data alive

In 2020, COVID-19 completely changed clinical trials in the pharmaceutical industry. We recently discussed these challenges in PharmaTimes Magazine, including how the pandemic has accelerated the crucial process of digital transformation.

Earlier in the year we commissioned a survey of life sciences professionals in collaboration with Phlexglobal and the Ethical Medicines Industry Group (EMIG).

The survey found that 70% of respondents felt that COVID-19 had triggered a change in the way clinical trials were conducted;

• Interoperability between eClinical applications used in trials remained a major challenge – for example, 39% of all respondents and 50% of CRO respondents were unable to convert documents from multiple eClinical applications;
• Archiving of clinical trial data was not always fit for purpose – for example, 65% of compliance, legal, and regulatory professionals described their ability to access data as ‘extremely inadequate’ or ‘very inadequate’.

There can be no doubt that digital technology will continue to play a key role in that change, both when it comes to the collection of data and in the way it is subsequently analysed and stewarded.

See the article in PharmaTimes Magazine for our full discussion about these findings.

You can find the full findings discussed in this article in our TMF Futures: Keeping Data Alive report.